• Blog
  • Opioid-Induced Constipation (OIC) Drug Market Growth Analysis

    Opioid-Induced Constipation (OIC) Drug Market Growth Analysis

    Opioid-Induced Constipation (OIC) Drug Market Growth Analysis
    Report code - SR1424 Delivery - 2 Weeks
    Opioid-Induced Constipation (OIC) Drug Market Growth, Trends, Dynamics & Market Insigh See more...

    Market Insights

    The Opioid-Induced Constipation (OIC) Drug Market was valued at US$ 1.7 Billion in 2020 and is projected to reach US$ 3.2 Billion by 2026, registering a CAGR of 11.1% during the forecast period.

    Wish to get a free sample? Register Here

    What is an opioid-induced constipation drug?

    Opioid-Induced Constipation (OIC) drugs are prescribed to patients with acute and chronic non-cancer pain. They reduce the secretion of digestive enzymes which results in opioid-induced constipation with several symptoms such as a bulged abdomen, distention, bloating, and painful defecation due to hard and dry stools.

    Opioid-Induced Constipation (OIC) Drug Market Highlights

    Market Size in 2026

    USD 3.2 billion

    Market Size in 2020

    USD 1.7 billion

    Market Growth (2021-2026)

    CAGR of 11.1%

    Base Year of Study

    2020

    Trend Period

    2016-2019

    Forecast Period

    2021-2026

    Key Players

    Key players operating in the Opioid-Induced Constipation (OIC) Drug market are-

    • AstraZeneca plc (UK)
    • Mallinckrodt Pharmaceuticals (UK)
    • Salix Pharmaceuticals Inc (US)
    • Merck & Co Inc (US)
    • Shionogi & Co Ltd (Japan)
    • Theravance Biopharma Inc (US)
    • Valeant Pharmaceuticals International (Canada)
    • Cosmo Pharmaceuticals SA (Ireland)
    • Daewoong Pharmaceutical (South Korea)
    • C B Fleet Company (US).

    Market Dynamics

    The key factor augmenting the market growth is a rising number of senior patients as these patients use opioid analgesics such as hydromorphone, morphine, codeine, etc. as a prescription for chronic non-cancer pain which has severe adverse effects on the digestive system resulting in huge demand for OIC drugs. Moreover, the increasing volume of patient pool with opioid users demands efficient medication for the OIC ailments which is likely to spur the industry growth during the review period.

    COVID-19 Impact

    The COVID-19 outbreak positively influenced the growth of the Opioid-Induced Constipation (OIC) Drug market. The pandemic caused added challenges for patients who are having some form of gastrointestinal infection. Due to social distancing, many hospitals have restricted appointments, and they were instead offering patient video conferencing to overcome the limitations of the market growth.

    To get the full scope of the report, Register Here

    Segment Analysis

    Drug Type Trends

    The market has been classified into Mu-opioid receptor antagonists, chloride channel-2 activators, and others. The Mu-opioid receptor antagonists segment accounted for a substantial market share in 2020. This is mainly attributed to the easy availability of several types of products launched by major players which are suitable for various symptoms in the OIC and the surge in research activities in the segment, which proliferates the segment growth.

    Regional Trends

    The market in North America accounted for the largest share in 2020 and is projected to continue its dominance during the review period. This is mainly ascribed to the increasing prevalence of various GI disorders among geriatric patients in the US and a steep rise in the consumption of opioids in Canada in the past few years. Moreover, the presence of established players in the market and funding for R&D activities further bolsters regional growth.

    To get the full scope of the report, Register Here

    Target Audience

    Here is the list of the group of customers that the opioid-Induced Constipation (OIC) drug market hopes to have the greatest opportunity to convert-

    • Distributors
    • Suppliers
    • Manufacturers
    • Logistics organizations
    • Government bodies

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

     

    What deliverables will you get in this report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth analysis of the Opioid-Induced Constipation (OIC) Drug Market

    How lucrative is the future?

    Market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional and country level historical data and forecasts

    Which are the most attractive market segments?

    Market segment analysis and forecast

    Which are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirement?

    10% free customization

    Research Methodology

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

    Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

    Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    Opioid-Induced Constipation (OIC) drugs are prescribed to patients with acute and chronic non-cancer pain. They reduce the secretion of digestive enzymes which results in opioid-induced constipation with several symptoms such as a bulged abdomen, distention, bloating, and painful defecation due to hard and dry stools.

    The opioid-induced constipation drug market is expected to witness an impressive growth of 11.1% CAGR in the coming years.

    AstraZeneca plc (UK), Mallinckrodt Pharmaceuticals (UK), Salix Pharmaceuticals Inc (US), Merck & Co Inc (US), Shionogi & Co Ltd (Japan), Theravance Biopharma Inc (US), Valeant Pharmaceuti-cals International (Canada), Cosmo Pharmaceuticals SA (Ireland), Daewoong Pharmaceutical (South Korea), and C B Fleet Company (US) are among the key players in the opioid induced constipation drug market.

    The opioid-induced constipation drug market size is expected to reach USD 3.2 billion in the foreseeable future.

    The Mu-opioid receptor antagonists segment accounted for a substantial share in the opioid constipation drug market in 2020.

    North America is expected to remain dominant in the opioid induced constipation drug market in the next five years.

    The key factor augmenting the market growth is a rising number of senior patients as these patients use opioid analgesics such as hydromorphone, morphine, codeine, etc. as a prescription for chronic non-cancer pain which has severe adverse effects on the digestive system resulting in huge demand for OIC drugs.